Fulcrum Therapeutics, Inc. (Nasdaq: FULC) said it is merging with Slate Medicines, Inc. to advance next-generation therapeutics to treat migraine and other headache disorders, with the combining company operating as Slate Medicines, Inc. and trading on Nasdaq under the ticker "SLTE." Slate reported it secured an oversubscribed concurrent private placement of $245 million from healthcare investors led by Frazier Life Sciences and including Forbion, RA Capital Management, and Deep Track Capital, among other firms. The new company's cash balance is expected to fund operations into 2029, it said. "Migraine remains one of the most prevalent and disabling neurological diseases, yet millions of patients continue to be underserved by existing therapies," said Gregory Oakes, Slate Medicines CEO.
"This merger and the related financing are expected to provide the resources to advance SLTE-1009, along with the rest of our pipeline, through potentially meaningful clinical milestones." The post Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies appeared first on ExecEdge.
Extract — continue reading at the source.
